EGFR and Familial prostate cancer: Table 9 shows pathways enriched in PPI network of PCOS-NIR vs. PCOS-IR. At a FDR of 0.01, 6 pathways were enriched, including pathways in cancer (FDR = 4.78E-08), chronic myeloid leukemia (FDR = 3.17E-05), and prostate cancer (FDR = 2.62E-04) (Table 9). Table 10 showed the enriched pathways in PPI network of PCOS vs. healthy controls. At a FDR of 0.01, 5 pathways were enriched, including pathways in cancer (FDR = 0.00112), ErbB signaling pathway (FDR = 0.001209), and focal adhesion (FDR = 0.001848) (Table 10).